Farrokh Modabber - Concepedia

Author

Farrokh Modabber

Also Known As

F MODABBER, F Modabber, F Z Modabber, F. MODABBER, F. Modabber, F. Z. Modabber, F.Z. Modabber, Farrokh Modabber, Farrokh Z Modabber, Farrokh Z. Modabber

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

World Health Organization Special Programme for Research and Training in Tropical Diseases Tehran University of Medical Sciences Drugs for Neglected Diseases Initiative Isfahan University of Medical Sciences

About

Farrokh Modabber is an author at World Health Organization specializing in medicine, immunology, and parasitology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	32	2.2K
2	Allergy	10	11	291
3	Health Sciences	1	1	42
4	Natural Sciences	1	1	18
5	Allergy Medicine	1	1	60

Farrokh Modabber

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial Shyam Sundar, Prabhat Kumar Sinha, Madhukar Rai, The Lancet Clinical EpidemiologyPharmacotherapyShort-course Multidrug TreatmentMedicineVisceral Leishmaniasis	2011	334
Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran Iraj Sharifi, Alireza Fekri, Mohammad-Reza Aflatonian, The Lancet VaccinationParasitic ProtozoaAnthroponotic Cutaneous LeishmaniasisVaccine TrialSingle Dose	1998	237
Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan A. M. A. El Hassan, EE Zijlstra, MM Mukhtar, The Lancet VaccinationVaccine DevelopmentVaccine TargetBcg-controlled TrialImmunology	2000	232
Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis Ali Khamesipour, Yahya Dowlati, Ali Asilian, Vaccine VaccinationOld MethodCandidate VaccinesParasitic ProtozoaMedicine	2005	205
Leishmaniasis vaccine candidates for development: a global overview. Ali Khamesipour, Sima Rafati, Noushin Davoudi, PubMed VaccinologyVaccinationVeterinary VaccineVaccine DevelopmentParasitic Protozoa	2006	192
A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran Ali Momeni, T Jalayer, Morteza Emamjomeh, Vaccine VaccinationVaccine SafetyControlled TrialZoonotic Cutaneous LeishmaniasisParasitic Protozoa	1999	150
Immunization with a Polyprotein Vaccine Consisting of the T-Cell Antigens Thiol-Specific Antioxidant,<i>Leishmania major</i>Stress-Inducible Protein 1, and<i>Leishmania</i>Elongation Initiation Factor Protects against Leishmaniasis Rhea N. Coler, Yasir A. W. Skeiky, Karen Bernards, Infection and Immunity	2002	143
Increased myelopoiesis during Leishmania major infection in mice: generation of 'safe targets', a possible way to evade the effector immune mechanism. Anna Mirkovich, A Galelli, A. C. Allison, PubMed Inflammation'Safe TargetsParasitic ProtozoaGranulocyteImmunology	1986	115
Methodology of Clinical Trials Aimed at Assessing Interventions for Cutaneous Leishmaniasis Piero Olliaro, Michel Vaillant, Byron Arana, PLoS neglected tropical diseases Translational MedicineAfrican TrypanosomiasisParasitic ProtozoaClinical TrialsPathology	2013	110
Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia Iván Darío Vélez, Katherine Gilchrist, María Patricia Arbeláez, Transactions of the Royal Society of Tropical Medicine and Hygiene	2005	96

Page 1